Zurich, Suisse (ots/PRNewswire) - - Knowledge Gap of Concern to Both Physicians and Patient Groups Nine out of ten patients battling cancer in Europe have never heard of a major breakthrough in cancer treatment, known as anti-angiogenesis, according to a new survey released today. Yet, 70% of cancer ...
Ottawa, Canada (ots/PRNewswire) - The MDS Nordion Equinox, a state-of-the-art cancer therapy system, and Avanza, a patient positioning treatment table, have received CE Mark approval and are now commercially available in Europe. The Equinox is a unique external beam therapy system providing cancer care professionals with modern functionality to maximize productivity and increase flexibility ensuring patients ...
Research Triangle Park, North Carolina (ots/PRNewswire) - - Emerging U.S. company Aerovance Inc. studying COPD drug in U.K. Quintiles Transnational Corp. today announced that it has reached a significant milestone in data management -- the 200th clinical trial using Electronic Data Capture (EDC). Quintiles is using EDC in a trial being conducted in the United Kingdom for Aerovance, Inc., of Berkeley, ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA) announced today preliminary 48 week clinical data obtained from its Phase III psoriasis and extension trials for its lead immunosuppressive drug, ISA247. Patients completing the 24 week Canadian Phase III SPIRIT trial were given the opportunity to continue therapy for an additional 36 weeks or to ...
Lugano/Johannesburg (ots) - HELSINN HEALTHCARE SA, and PFIZER LABORATORIES (PTY) LTD, announce the signing of an agreement granting PFIZER in South Africa, the exclusive license and distribution rights of Aloxi® (Palonosetron hydrochloride), a therapy for the prevention of nausea and vomiting induced by ...
Toronto, Canada (ots/PRNewswire) - There are 18 million undernourished people and 7.5 million at risk of starvation and after six years of drought, crops across East Africa have failed again. National governments, local authorities and the United Nations need to respond in a timely matter as we have the means ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. will announce preliminary 48 week clinical trial data for the Company's Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247, on Monday, March 20th at 8:00 a.m. EST/6:00 a.m. MST. Management will provide an overview of the preliminary 48 week Phase III data following the release ...
Vienna, Austria (ots/PRNewswire) - - New Data Demonstrate "Unique", Five Year Anti-Osteoporotic Efficacy Against Both Vertebral and Non-Vertebral Fractures New five year data presented at the 6th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ECCEO 6) meeting today show that the new osteoporosis treatment Protelos(R) ...
Tokyo, Japan (ots/PRNewswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) today announced preliminary results from the latest donepezil (Product name: ARICEPT(R)) study (Study 319) on the treatment of people with vascular dementia (VaD). Preliminary efficacy results show that those who received donepezil improved on measures of cognition, ...
Lyon, France (ots/PRNewswire) - - Influenza Vaccine Worldwide Leader sanofi pasteur Contributes to Italian Influenza Pandemic Preparedness Sanofi pasteur, the vaccines business of the sanofi-aventis Group(EURONEXT: SAN; NYSE: SNY), has supplied to the Italian Ministry of Health a stock of pre-pandemic vaccine against the H5N1 avian influenza virus ...
Ingelheim, Germany (ots/PRNewswire) - - For Non-US Healthcare Professional Media Boehringer Ingelheim announced today that that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of Sifrol(R) / Mirapexin(R) ...
Madrid (ots/PRNewswire) - Group: - Capital increase at Zeltia. The placement of 10.75 million new shares among qualified international investors raised 65 million euro - R&D expenditure up 24% - Net revenues in 2005: 72 million euro - Net cash position at 31 December 2005: 93 million euro net of short-term financial debt and 51 million euro net of total financial debt PharmaMar: - Yondelis(R): - Phase III pivotal trial on ovarian cancer ...
Lugano, Switzerland and Stockholm, Sweden (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and BIOVITRUM AB, a Swedish Biotechnology company, announce the signing of an agreement granting BIOVITRUM the exclusive License and Distribution rights of Aloxi® (Palonosetron hydrochloride) in the NORDIC ...
London, England and Philadelphia, Pennsylvania (ots/PRNewswire) - GlaxoSmithKline plc (GSK) announced today the commencement of a worldwide clinical trial to investigate the safety and efficacy of eltrombopag (SB-497115-GR) as a once-daily orally-administered drug for adult patients with previously-treated ...
Lugano (ots) - HELSINN HEALTHCARE SA signed an Agreement with THERABEL PHARMA under which it granted THERABEL PHARMA the exclusive License and Distribution rights to distribute, market and sell Aloxi® (palonosetron hydrochloride) in France, Belgium, Luxemburg and The Netherlands. Aloxi® is a strong and long-lasting antiemetic belonging to ...
Madrid, Spain (ots/PRNewswire) - PharmaMar announced today that its Investigational New Drug application (IND)[1] has been accepted by the US Food and Drug Administration (FDA) for the clinical testing of Zalypsis(R) (PM00104/50), PharmaMar's novel marine anti-tumour agent. Zalypsis is already in Phase I clinical development in Europe, where three multicenter ...
Callisto Pharmaceuticals. Inc.
New York (ots/PRNewswire) - - Drug Class Developed at The University of Texas M. D. Anderson Cancer Center Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, has announced that it signed an agreement with ...
Basel, Switzerland and Morrisville, North Carolina (ots/PRNewswire) - - Early Preclinical Data on TR-291144 and TR-290999 to be Presented at Major HIV Congress in February BASEL, Switzerland and MORRISVILLE, North Carolina, January 19 /PRNewswire/ -- Roche and Trimeris today announced their collaboration ...
Geneva and Singapore (ots/PRNewswire) - STMicroelectronics (NYSE: STM) and Veredus Laboratories today announced that they are developing a fast, point-of-need diagnostic capability that will enable health practitioners to quickly detect strains of Avian Flu and other influenza viruses. The diagnostic capability, ...
Dreieich/Wolfsburg (ots) - The city of Wolfsburg is home to Volkswagen, the car makers. Its reputation to date has mainly been as a motor of progress in the development of modern production methods for the automotive industry. But Wolfsburg is now about to make a name for itself as a European pioneer in implementing better strategies for preventing cervical cancer. ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company enrolled its first patient in a North American Phase IIb kidney transplant trial for its lead immunosuppressive drug, ISA247, on January 4, 2006. The trial will be performed at thirty-four centers across North America , including twenty-nine centers in the United States and ...
Darmstadt, Germany (ots/PRNewswire) - Merck KGaA today announced an organizational change in the Merck Generics Group (MGG), naming J. Melville ("Mel") Engle to the post of MGG Regional Director, North America. Mr. Engle will retain his current position of President and Chief Executive Officer of Napa, CA-based DEY, L.P., a Merck subsidiary. (Photo: ...
Ludwig-Maximilians-University of Munich
Munich, Germany (ots/PRNewswire) - A new study published today in the European Archives of Psychiatry and Clinical Neuroscience demonstrates that quetiapine (SEROQUEL) and risperidone (RISPERDAL) have equivalent efficacy in the treatment of patients with schizophrenia exhibiting predominately negative symptoms, ...
Alderley Park, England (ots/PRNewswire) - - Filing Seeks Approval of SEROQUEL as a Monotherapy Treatment for Bipolar Depression AstraZeneca today announced submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) to seek approval for a new indication for SEROQUEL(R) (quetiapine fumarate) for the treatment of ...
Lyon, France (ots/PRNewswire) - Sanofi pasteur, the vaccines business of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), has entered into an agreement with BD (Becton, Dickinson and Company) (NYSE: BDX) to license the Micro-Delivery technology of BD Medical-Pharmaceutical Systems for use in the administration of sanofi pasteur's human vaccine products. ...
Basel, Switzerland (ots/PRNewswire) - - Power of "FUZEON effect" Provides Much Needed Hope for HIV Patients Facing Treatment Failure Exciting interim data presented at the annual ICAAC(i) conference show that adding FUZEON (enfuvirtide) to the investigational boosted protease inhibitor (PI), TMC114/r, more than doubles the proportion of patients reaching ...
Madrid (ots/PRNewswire) - - IDMC Recommends Adoption of 24hr Dosing in Pivotal Trial PharmaMar today announces that the independent data monitoring committee (IDMC) for the pivotal trial of YONDELIS(R) in Soft Tissue Sarcoma (STS) has reviewed data from a pre-planned interim analysis of the primary end-point, Time to Progression (TTP), which indicate that ...
Lyon, France (ots/PRNewswire) - - Data Show That the Vaccine is Safe, Demonstrates Immunogenicity and Provides Future Direction for Development Sanofi pasteur, the vaccines business of the sanofi-aventis Group, announced today that preliminary results of clinical trials fielded in France of an adjuvanted ...
Alderley Park, England (ots/PRNewswire) - AstraZeneca announced today that it has received positive opinion from the Committee for Orphan Medicinal Products (COMP) recommending orphan drug designation for ZD6474 (ZACTIMA(TM)) for the treatment of patients with medullary thyroid cancer in the European Union (EU). ...
Madrid (ots/PRNewswire) - PharmaMar today announces the results of the Aplidin(R) Phase II trial which were presented at the American Society of Hematology 47th Annual Meeting in Atlanta, Georgia, USA, on Sunday 11 December. Aplidin reached its objective of overall response rate established in the first stage of ...